Inhaled medications for Asthma and COPD (prior authorization and quantity limits)
Covers prior authorization, quantity limit (Quality Care Dosing) requirements, formulary status, and medical necessity criteria for inhaled medications used to treat Asthma and COPD for BCBSMA commercial plans; includes provider documentation and individual consideration processes.
7/2024: Update to remove prior authorization of Breyna and other generics of Budesonide/Formoterol.
4/2024: Require diagnosis for Trelegy and Breztri to align with rest of the policy.
2/2024: Updated to add Fluticasone/Salmeterol to COPD part of Breo Ellipta's Criteria and to other drugs where it was missing.
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.